Could the time of day you get immunotherapy boost your survival?

NCT ID NCT07155317

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times

Summary

This study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning improves their effectiveness for people with advanced melanoma that cannot be surgically removed. About 99 adults with stage IV melanoma will be randomly assigned to receive treatment in the morning, afternoon, or at their usual time. The goal is to see if timing affects how long the cancer stays under control and whether it reduces side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Emory Saint Joseph's Hospital

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30342, United States

    Contact

    Contact Email: •••••@•••••

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.